September 2023

September 2023

Peer Reviewed Feature Articles

Obstructive airway diseases

The GINA 2023 report. What’s new in asthma management?

Helen K. Reddel

The Global Initiative for Asthma released its updated global strategy for asthma prevention and management earlier this year. As-needed combination low-dose ICS-formoterol is recommended as first-line treatment over short-acting beta2-agonists alone for adults and adolescents aged 12 years and older.

Interstitial and parenchymal lung diseases

Drug-induced interstitial lung disease – a heterogeneous old foe with an evolving new face

Senthuran Shivakumar, Yet Hong Khor

The incidence of drug-induced interstitial lung disease is likely to increase in the future with advances in drug development. The cornerstone of management is early detection and cessation of the inciting medication.

Critical care and acute respiratory failure

Preterm lung disease: not just for neonatologists

Denby J. Evans, James T.D. Gibbons , Shannon J. Simpson, John Blakey

Preterm birth can increase the risk of respiratory disease from infancy through to adulthood. When was the last time you asked if your patient was born prematurely?

Peer Reviewed Regular Series

Perspectives

Frailty and chronic lung disease: a silent overlap in need of attention

Christian Osadnik

Frailty often occurs concurrently with chronic lung disease. However, due to overlapping risk factors, the impact of frailty is overlooked, particularly in younger patients with chronic lung disease. Maintaining vigilance for frailty indicators and co-ordinated multidisciplinary input can enhance early detection and management.

Perspectives

Vaping and the government’s new approach: what GPs need to know

Matthew J. Peters

In May 2023, policy changes were introduced to tackle the growing use of electronic cigarettes and their associated harms. These changes pose some novel challenges for GPs, as they play a pivotal role in addressing this public health issue.

Briefings